Prokidney
The purpose of this study is to evaluate the long-term safety, efficacy, and durability in participants with chronic kidney disease (CKD) who received up to four REACT injections, delivered percutaneously into either the same or bilateral kidneys in previous studies.
This observational extension study is a multi-center, prospective, non-therapeutic study, where up to 50 participants who have been enrolled and dosed with Renal Autologous Cell Therapy in previous interventional clinical studies (REGEN-007, REGEN-006, REGEN-015) will be monitored for up to five years with alternating in clinic and phone visits.
Inclusion Criteria: * The participant must have received REACT in a previous trial (REGEN-006, REGEN- 007, and REGEN-015) for the treatment of chronic kidney disease and completed an end of study visit in their previous trial per protocol. * The participant is willing and able to cooperate with all aspects of the protocol. * The participant is willing and able to provide signed informed consent. Exclusion Criteria: • Participant did not receive REACT in a previous trial for the treatment of chronic kidney disease
No interventions in this trial
Arctuva estimate
Verify or correct the compensation shown for this listing.